

Article

Not peer-reviewed version

---

# Prediction of Microvascular Adaptation to Hypoxia Based on Myogenic Microcirculation Oscillations

---

[Andrzej Marcinek](#)<sup>\*</sup>, Joanna Katarzynska, [Artur Stanek](#), [Jerzy Gebicki](#)<sup>\*</sup>

Posted Date: 28 March 2025

doi: 10.20944/preprints202503.2080.v1

Keywords: microcirculation; myogenic oscillations; hypoxia sensitivity; NADH fluorescence; FMSF technique



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Article

# Prediction of Microvascular Adaptation to Hypoxia Based on Myogenic Microcirculation Oscillations

Andrzej Marcinek <sup>1,2,\*</sup>, Joanna Katarzynska <sup>2</sup>, Artur Stanek <sup>3</sup> and Jerzy Gebicki <sup>1,2,\*</sup>

<sup>1</sup> Institute of Applied Radiation Chemistry, Lodz University of Technology, 90-924 Lodz, Poland

<sup>2</sup> Angionica Ltd., 90-924 Lodz, Poland

<sup>3</sup> Hypoxico Polska Ltd., 42-202 Czestochowa, Poland

\* Correspondence: A.M, andrzej.marcinek@p.lodz.pl or andrzej.marcinek@angionica.com.pl, tel.: +48 42 631 30 96; J. G. jerzy.gebicki@p.lodz.pl or jerzy.gebicki@angionica.com.pl, tel.: +48 42 631 31 71

**Abstract:** Microcirculatory oscillations known as flowmotion are a recognized feature of blood flow that reflect the functional state of the vascular system. Many diseases are associated with impaired flowmotion, especially diseases that are accompanied by hypoxia. Low frequency myogenic oscillations (0.052–0.15 Hz) are an important regulator of microvascular adaptation to hypoxia. Here, we study the myogenic component of flowmotion using the FMSF–PORH (Flow Mediated Skin Fluorescence–Post Occlusive Reactive Hyperemia) technique. Myogenic oscillations were strongly activated under hypoxic conditions caused by occlusion of brachial artery or intermittent hypoxic treatment. A strong correlation was noted between the hypoxia sensitivity parameter HS (the intensity of myogenic oscillations activated by hypoxia) and the normoxic myogenic flowmotion parameter VM (the intensity of myogenic oscillations under normoxia conditions). If HS is considered as a direct measure of the microcirculation response to hypoxia, then VM can be considered a measure of the microcirculation's readiness to provide this response. The assessment of myogenic activity under normoxia conditions could thus provide a simple and rapid diagnostic tool for health care practitioners.

**Keywords:** microcirculation; myogenic oscillations; hypoxia sensitivity; NADH fluorescence; FMSF technique

## 1. Introduction

Microcirculatory blood flow oscillations known as flowmotion are a direct result of vasomotion—i.e., fluctuations in vessel diameter, synchronous dilation of vessels or constriction over the time. Vasomotion quality differs between vascular beds and is of significant importance for microcirculation, especially under pathological conditions when blood supply to the organ is impaired. The mechanistic aspects of flowmotion, especially its role in ensuring the proper perfusion of tissues, have been the subject of extensive research [1–10].

Microcirculation is mostly studied in humans at the level of skin, partly because skin remains the most accessible measurement site. More importantly, however, skin microcirculation dysfunction mirrors impairment of microcirculation and blood flow oscillations in other organs. The majority of data on flowmotion is collected via measurements of blood flow (laser-Doppler flowmetry, LDF, laser speckle contrast imaging, LSCI), local blood pressure readings, or volume measurements (peripheral arterial tonometry, plethysmography) [2,11–15].

Flowmotion oscillations depend to some extent on the pulse (cardiac component, frequency around 1 Hz) and pulmonary pressure variations (respiratory-dependent component, 0.15–0.6 Hz). However, lower frequency oscillations in the microcirculation play a more important role. These can be subdivided into three groups: oscillations dependent on the vascular endothelium (endothelial

component,  $\leq 0.021$  Hz), neurogenic activity (neurogenic component, 0.021–0.052 Hz), and smooth muscle activity (myogenic component, 0.052–0.15 Hz) [4,14,16–22].

Impaired flowmotion is associated with many diseases and disorders, including diabetes, hypertension, cardiovascular diseases, peripheral artery disease, chronic wounds, tumour progression, and erectile dysfunction [1–10]. In all these cases, a weakening of flowmotion is observed. For example, a large-scale Maastricht study (over 7200 participants) on flowmotion in diabetes type 2 (DM2) revealed a negative correlation between skin microvascular flowmotion and different measures of hyperglycemia. The decrease in flowmotion intensity applied to all low-frequency components of the oscillations [23].

Recently, we introduced Flow Mediated Skin Fluorescence (FMSF), a novel non-invasive diagnostic technique based on the measurement of nicotinamide adenine dinucleotide (NADH) fluorescence from skin tissue cells. The NADH/NAD<sup>+</sup> redox state is an extremely sensitive internal marker for any changes in blood circulation and the delivery of oxygen to epidermal cells. The diagnostic potential of the method is based primarily on stimulation of the circulation in response to post-occlusive reactive hyperemia (PORH). The FMSF–PORH technique has been described in detail in numerous publications [24–29].

In contrast to changes in blood flow observed upon full dilation and constriction of large arteries, microcirculation flowmotion is of intermediate intensity [3,30]. The NADH fluorescence signal during hyperemia/reperfusion changes by up to about 20–30%. This hyperemic response ( $HR_{max}$ ) is analogous to that in LDF and LSCI [15,31]. The changes during occlusion also reach about 15–25% of total fluorescence (unfortunately, other methods using PORH based on blood flow and local pressure changes remain “blind” during the occlusion period). The amplitude of the oscillations on the baseline (normoxia conditions) is on the order of 0.5% of the total fluorescence level and increases to 1–2% on the reperfusion line. Due to very low noise, the oscillations are clearly visible, including the cardiac component, which is several orders of magnitude weaker than the low-frequency oscillations. On the reperfusion line, the myogenic oscillations are so distinct that their frequency and amplitude can be determined without any complicated analysis [27–29].

In this study, we will focus only on myogenic oscillations and their role as an important regulator of microvascular adaptation to hypoxia. Myogenic vasomotion and the resulting myogenic flowmotion is controlled by Ca<sup>2+</sup> oscillation in vascular smooth muscles, involving the periodic release of Ca<sup>2+</sup> stores, oscillations in membrane depolarization, and elevated global cytosol Ca<sup>2+</sup> concentrations [2,5,30,32]. Myogenic activity has been shown to be closely associated with effective oxygen delivery and increased hypoxia [33]. Increased myogenic oscillations have also been observed using LDF in mountain climbers ascending to high altitudes (above 3500 m). Increases in myogenic activity play a significant role in the adaptation of Sherpas highlanders to hypobaric hypoxia [34–36]. The activation of myogenic oscillations may therefore accompany hypoxic conditions present in numerous diseases, and could be used to assess microcirculatory functioning in diabetes, cardiovascular disease, peripheral arterial disease, and hypertension, as well as physical exercise tolerance [27]. Activation of vasomotion under hypoxic conditions also raises the question of how prevalent myogenic oscillations are under normal normoxic conditions, in both healthy and diseased individuals [2].

## 2. Materials and Methods

### *Brief Description of the Analysed Groups*

The analysis involved two main patient groups. One was a group of 910 patients with vascular diseases (CVD) and/or type 2 diabetes (DM2), as described in previous publications [10,29,37]. The second main group (control) consisted of healthy volunteers (77), athletes (76, amateur sportsmen (26), and endurance athletes (50)), as described previously [38–43]. A third group of athletes consisted of 56 individuals (amateur sportsmen (26) and endurance athletes (30), average age 25.7 years), who were subjected to exertion to exhaustion. The final group comprised 9 competitive and amateur

athletes (average age 26.2 years) given intermittent hypoxia treatment (IHT). The characteristics of the groups are displayed in Table 1.

**Table 1.** Characteristics of the groups studied.

	Control group	CVD+DM2 group	Athletes group		IHT group	
			before exertion to exhaustion	after exertion to exhaustion	before intermittent hypoxia treatment	after intermittent hypoxia treatment
N	153	910 AH (508) CVD (475) DM2 (273)	56		9	
Female/ Male	34 / 119	519 / 391	10 / 46		4 / 5	
Age [years]	32.6 ± 11.7	67.6 ± 12.5	25.7 ± 4.8		26.2 ± 10.4	
BMI [kg/m <sup>2</sup> ]	24.3 ± 4.0	28.9 ± 5.8	22.4 ± 2.4		20.6 ± 1.7	
DBP [mm Hg]	77.1 ± 10.3	74.9 ± 10.7	71.3 ± 7.7	72.9 ± 8.1	69.2 ± 7.8	72.2 ± 7.3
SBP [mm Hg]	130.4 ± 13.9	137.5 ± 18.1	129.7 ± 12.2	158.4 ± 19.8	118.3 ± 12.3	112.9 ± 7.8
IR <sub>max</sub> [%]	16.3 ± 5.8	11.4 ± 5.6	18.6 ± 5.2	13.1 ± 5.4	20.1 ± 8.5	19.5 ± 4.1
HR <sub>max</sub> [%]	19.8 ± 4.6	16.5 ± 5.1	20.6 ± 4.7	19.9 ± 4.8	18.5 ± 5.4	19.9 ± 5.6
log(VM)	1.23 ± 0.50	0.53 ± 0.58	1.32 ± 0.53	0.99 ± 0.52	1.06 ± 0.39	1.34 ± 0.34
log(HS)	1.80 ± 0.44	1.14 ± 0.56	1.91 ± 0.41	2.04 ± 0.43	1.89 ± 0.20	1.95 ± 0.22


Note: Continuous variables, mean ± SD. Abbreviations: AH, Arterial Hypertension; CVD, Cardiovascular Disease; DM, Diabetes Mellitus; BMI, Body Mass Index; DBP, Diastolic Blood Pressure; SBP, Systolic Blood Pressure; IR<sub>max</sub>, Ischemic Response maximal; HR<sub>max</sub>, Hyperemic Response maximal; log(VM), Vasomotion (logarithm); log(HS), Hypoxia Sensitivity (logarithm).

All formal regulations concerning the collection of experimental data were respected and the patients were informed that the conducted measurements may be published under conditions of full confidentiality and anonymity.

#### *The FMSF Methodology*

The FMSF technique measures NADH fluorescence from the skin, mainly on the forearm. The methodological aspects of the FMSF method have been investigated and described in depth [24–26,40]. The diagnostic potential of the FMSF method is based primarily on stimulation of the circulation in response to post-occlusive reactive hyperemia (PORH) caused by the occlusion of a brachial artery, resulting in severe hypoxia in the limb downstream. Sudden release of the occluded artery causes reactive hyperemia, followed by reperfusion period of a few minutes. Before and after occlusion, strong flowmotion oscillations are observed (Figure 1A). Using the Fast Fourier Transform (FFT) algorithm, the share of each low-frequency oscillation components can be determined, including myogenic oscillations, the myogenic component of flowmotion. Under conditions of

normoxia, vascular myogenic activity results in normoxic vascular myogenic oscillations (VM), which usually remain the weakest of the low-frequency oscillations. In contrast, oscillations after occlusion are dominated by the myogenic component and their intensity is referred to as hypoxia sensitivity (HS) (Figure 1). Both VM and HS are power spectra densities (PSD), calculated as the mean squared amplitude of myogenic oscillations under normoxia or hyperemia/reperfusion conditions, respectively, multiplied by a factor  $10^6$ . Whereas the VM and HS parameters vary within a very broad range, their logarithms remain normally distributed and can be used for statistical comparisons. Both numerical values are measured in arbitrary units.



**Figure 1.** FMSF traces recorded for a physically active individual, male, age 40-45 y. before (A) and after (B) a single session of intermittent hypoxia treatment (duration 55 min, 5 min hypoxia at 9% O<sub>2</sub> followed by 5 min normoxia at 21% O<sub>2</sub>).

### Statistical Analysis


Statistical analyses were performed using OriginPro 2024 software. The normality of the distribution was determined using the Shapiro–Wilk test. A two-sided *t*-test was used for the group comparison. The Pearson’s correlation coefficient was calculated to assess the relationship between the continuous variables  $\log(\text{VM})$  and  $\log(\text{HS})$ . The receiver operating characteristic (ROC) curve and the area under the curve (AUC) were calculated to set thresholds for the VM parameter. Sensitivity/specificity analysis was conducted to assess the predictive ability of the VM parameter to identify subjects with optimal, acceptable, and impaired adaptation of the microcirculation to hypoxia. A *p*-value of less than 0.05 was considered statistically significant.

## 3. Results and Discussion


The oscillatory changes in the NADH/NAD<sup>+</sup> balance associated with hypoxia, and therefore the oscillations of NADH fluorescence monitored by the FMSF-PORH method, reflect microvascular vasomotion activated by occlusion of the brachial artery for 3 minutes. Myogenic oscillations are activated immediately following the occlusion, upon the release of blood flow. Their intensity (HS parameter) may be related to the instantaneous induction of HIF-1 $\alpha$  in microvascular smooth muscle cells during transient hypoxia [44]. The better adaptation of microcirculation to hypoxia, the stronger activation of myogenic oscillations (higher values of HS). In the case of serious microcirculation disorders, myogenic oscillations remain very low and do not respond at all to hypoxic conditions causing NADH/NAD<sup>+</sup> imbalance.

An example of an FMSF-PORH course with spectacular activation of myogenic oscillations upon occlusion is presented in Figure 1A, for an active amateur athlete. Occlusion of the brachial artery for

3 minutes caused an over tenfold increase in the intensity of hypoxic myogenic oscillations HS (hyperemia/reperfusion period) vs normoxic myogenic oscillations VM (baseline before the occlusion period) (see Figure 1A, VM = 11.6 (log(VM) = 1.06), HS = 150.6 (log(HS) = 2.18)). For the control group of 153 healthy volunteers and sportsmen, the myogenic oscillations under normoxia conditions log(VM) = 1.23 increased to log(HS) = 1.80 in response to transient hypoxia (see Table 1). The mutual relationship of log(HS) vs log(VM) is well described by a linear relationship, with high Pearson's correlation coefficients (see Figure 2A):  $\log(\text{HS}) = (0.56 \pm 0.06) \cdot \log(\text{VM}) + (1.11 \pm 0.07)$ ,  $r = 0.639$ ,  $p < 0.0001$ . Both VM and HS parameters vary in a wide range of values (log(VM) = 0 ÷ 2.3, log(HS) = 0.7 ÷ 2.7; see Figure 3A and B).



**Figure 2.** Linear correlation between the log(HS) and log(VM) parameters for the control group (A) and the CVD+DM2 group (B).



**Figure 3.** Distributions of the VM and HS parameters for myogenic oscillations (A) under normoxia conditions (log(VM)) and (B) in response to brachial artery occlusion (log(HS)) for the control group and patients with CVD+DM2 diseases.

The remarkable increase of myogenic activity is a response to hypoxia in the upper limb of the patient, caused by an occlusion (3 min) of the brachial artery in the PORH method. It is worth noting that such a long period of occlusion may cause some physical discomfort, anxiety, or even pain during measurement and so this methodology cannot be used for children or disabled persons.

As mentioned previously, reduced vasomotion often accompanies various diseases. For example, experimental results show significant differences in normoxic myogenic flowmotion between diabetic patients, prediabetic patients, and nondiabetic people [23]. Determining microvascular proper functioning and detecting dysfunction could play an important role in the pre-diagnosis of diabetic complications [4].

Recent studies using the Flow Mediated Skin Fluorescence (FMSF) technique performed for a group of 910 cardiovascular (CVD) and type-2 diabetic patients (DM2) have shown that the VM parameter, reflecting the intensity of myogenic microcirculatory oscillations under normoxia conditions (without occlusion of the brachial artery), correlates strongly with the HS parameter, which reflects the intensity of myogenic microcirculatory oscillations following hypoxia induced by occlusion of the brachial artery. Figure 2 shows the correlations of  $\log(\text{HS})$  vs  $\log(\text{VM})$  observed for each group: A – control group, B – CVD+DM2 group. The linear dependence found for the CVD+DM2 group (see Figure 2B) of  $\log(\text{HS}) = (0.62 \pm 0.03) \cdot \log(\text{VM}) + (0.81 \pm 0.02)$ ,  $r = 0.636$ ,  $p < 0.0001$  remains similar to that found for healthy control group.

The intensity of myogenic oscillations in these disease entities (CVD, DM2) ranges predominantly towards lower values of  $\log(\text{VM}) = -1.3 \div 2.4$  and  $\log(\text{HS}) = -0.8 \div 2.5$  in relation to the control group (see Figure 3A and B). Although both linear dependences  $\log(\text{HS})$  vs  $\log(\text{VM})$  have similar slopes, in the case of the healthy control the same VM value corresponds to higher HS values than in the case of CVD+DM2 patients. In the control group, no individuals were observed with  $\log(\text{VM}) < 0$ , and in the CVD+DM2 group there were no patients with  $\log(\text{HS})$  higher than 2.5.

The strong correlation between  $\log(\text{HS})$  and  $\log(\text{VM})$  allows the intensity of the response to hypoxia ( $\log(\text{HS})$ ) to be predicted based on the assessment of normoxic myogenic oscillations ( $\log(\text{VM})$ ) under normoxia conditions. Three ranges of HS have been proven to be indicative of different conditions of the microvascular circulation, possessing diagnostic importance ( $\text{HS} < 10$ ,  $\log(\text{HS}) < 1$ ,  $10 \leq \text{HS} < 30$ , and  $\text{HS} \geq 30$ ,  $\log(\text{HS}) \geq 1.48$ ) [28,45]. Based on these three ranges for HS, diagnostic ranges for VM with similar meaning and importance can be selected: impaired VM ( $\text{VM} < 2$ ,  $\log(\text{VM}) < 0.30$ ), acceptable VM, ( $2 \leq \text{VM} < 12$ ), and optimal VM ( $\text{VM} \geq 12$ , ( $\log(\text{VM}) \geq 1.08$ ) (see Figure 3A and B).

The proposed partition of VM ( $\log(\text{VM})$ ) into appropriate ranges does not significantly disturb the population of individuals diagnosed with impaired microvascular function, 32–38% in the CVD+DM2 patient group and only 3% in the control group, if we compare the partition of groups by  $\log(\text{VM})$  with respect to the same partition by  $\log(\text{HS})$ .


Linking the relation of  $\log(\text{VM})$  with  $\log(\text{HS})$  via a linear relationship leaves some uncertainty regarding cases of false predictions of the proper response to hypoxia (HS) based on VM. Approximately 10% of all cases have  $\log(\text{VM})$  below 0.3, but at the same time  $\log(\text{HS}) \geq 1$  (false negative group) while approx. 16% of all cases are those with  $\log(\text{VM}) > 0.3$ , but at the same time  $\log(\text{HS}) < 1$  (false positive group). In part, this may result from measurement uncertainties. It is therefore advisable to repeat measurements for patients from impaired and acceptable groups. However, it may also be a real physiological effect. It is not an effect of age, since the  $\log(\text{VM})$  and  $\log(\text{HS})$  parameters for the group of cardiovascular and type 2 diabetes patients show a statistically significant dependence on age, and in both cases it is very similar (decreasing about 0.012 a.u. per year, see Table 2). Dependence on age is also similar to that found for the control group and remains in agreement with the literature and our previous observations [10,46].

**Table 2.** Linear dependence of  $\log(\text{VM})$ ,  $\log(\text{HS})$  on age.

Control group			CVD+DM2 group		
slope [a.u./year]	<i>r</i> (Pearson coefficient)	<i>p-value</i>	slope [a.u./year]	<i>r</i> (Pearson coefficient)	<i>p-value</i>

<b>log(VM) vs</b>	-0.017 ±			-0.012 ±		
<b>age</b>	0.003	-0.385	<0.0001	0.002	-0.264	<0.0001
<b>log(HS) vs</b>	-0.012 ±			-0.013 ±		
<b>age</b>	0.003	-0.311	<0.0001	0.002	-0.280	<0.0001

Possibly, this may be the result of chronic hypoxia or fatigue of the body due to a long-term disease, which in some patients translates into weakening or strengthening of myogenic oscillations under normoxia conditions, while maintaining the full potential of the hypoxia sensitivity (HS) response. Figure 4 shows such examples obtained for athletes and physically active individuals.



**Figure 4.** Changes in myogenic oscillations under normoxia conditions (log(VM)) and in response to brachial artery occlusion (log(HS)) before and after exertion to exhaustion for amateur and endurance athletes.


From the group of tested athletes, 26 amateur athletes and 30 endurance athletes exercised to exhaustion after the first FMSF-PORH measurement (Session 1: Exertion to exhaustion-before). The measurement performed again after this effort (Session 2: Exertion to exhaustion-after) indicated not only the almost complete disappearance of endothelial oscillations, as shown and discussed in our previous work [42], but also a significant decrease in myogenic oscillations VM for all athletes (session before exercise  $\log(\text{VM}) = 1.32$  vs session after exercise  $\log(\text{VM}) = 0.99$ ,  $p < 0.001$ ) (see Table 1, Figure 4). Despite the strong fatigue effect, the hypoxia sensitivity response (HS) remained almost unchanged (or even increased slightly but statistically insignificantly). Given the strong increase in myogenic oscillations in response to brachial artery occlusion (log(VM) vs log(HS)), also presented in Figure 4, monitoring of changes in HS and VM can be considered as an important element of a well-planned all-day training cycle.

The opposite effect was observed as a result of a single session of intermittent hypoxia treatment, which is not such an extreme hypoxic event as exertion to exhaustion. As can be seen for the amateur sportsman and a group of few volunteers (see Table 1), a single hypoxia treatment does not affected hypoxia sensitivity significantly,  $\text{HS} = 150.6$  ( $\log(\text{HS}) = 2.18$ ) in Figure 1A vs  $\text{HS} = 246$  ( $\log(\text{HS}) = 2.39$ ) in Figure 1B. However, in this case increased VM was observed after the intermittent hypoxia session,  $\text{VM} = 11.6$  ( $\log(\text{VM}) = 1.06$ ) in Figure 1A vs  $\text{VM} = 38.3$  ( $\log(\text{VM}) = 1.58$ ) in Figure 1B. This increase is a residual effect of myogenic oscillations in response to hypoxia during the hypoxia session, as the second measurement was taken immediately after the treatment.

Both of the above-mentioned experiments clearly indicate strong stabilization of the HS response, which is a direct measure of microvascular response to hypoxia. However, it should be remembered that hypoxia sensitivity (HS) may be affected by drugs or supplements which, through the increase of NO in vivo, transiently improve vascular circulation. It also shows some variability in the VM parameter, of approx.  $\pm 0.3$  a.u. of  $\log(\text{VM})$  for athletes usually characterized by strong

normoxic myogenic oscillations. Despite these uncertainties, the VM-based prediction of the myogenic oscillatory response to hypoxia seems an interesting alternative to measurements with brachial artery occlusion and assessment of the HS parameter, especially if more attention is paid to the results in the immediate vicinity of the threshold values.

The selection of the threshold values of VM was subjected to more detailed analysis, especially the cut-off value for the impaired VM range. The receiver operating characteristic curve (ROC) was obtained for all 1063 tested individuals (Control, CVD, DM2), assuming a proper response to hypoxia as  $\log(\text{HS}) \geq 1$ , and impaired response as  $\log(\text{HS}) < 1$ . The obtained AUC (area under curve) = 0.849 value confirms the predictive potential of VM. However, it is clearly seen from the ROC curve presented in Figure 5 that the initially selected threshold value of  $\log(\text{VM}) = 0.3$  ( $\text{VM} = 2$ ), although a highly sensitive predictor of the proper response to hypoxia (Sensitivity, TPR = 0.87), is not optimal in relation to the other ROC characteristics, especially Specificity (TNR = 0.58). The most optimal threshold value would be  $\log(\text{VM}) = 0.5$  ( $\text{VM} = 3.2$ ); not much less optimal is  $\log(\text{VM}) = 0.4$  ( $\text{VM} = 2.5$ ).




**Figure 5.** Receiver operating characteristic curve (ROC) obtained for all 1063 tested individuals (Control, CVD, DM2).

The advantage of choosing  $\log(\text{VM}) = 0.4$  as the cut-off value is the high value of TPR = 0.83 and the significantly increased value of TNR = 0.69, while maintaining the percentage of indications for the impaired response to hypoxia at the same level of about 34–35%, both using the HS parameter directly or its prediction based on VM.

Analysis of the ROC curve for the upper threshold, assuming an optimal response to hypoxia of  $\log(\text{HS}) \geq 1.48$  (AUC = 0.81), indicates an optimal cut-off value for  $\log(\text{VM}) = 0.7\div 1.0$ . A similar percentage of indications for the range of optimal responses to hypoxia (33–35%), both using the HS parameter directly or its prediction based on VM is obtained for a cut-off value of  $\log(\text{VM}) = 0.9$ ,  $\text{VM} = 8$  (TPR = 0.62, TNR = 0.83).

As more results are obtained, the limits of the VM ranges can be adjusted accordingly.

Figure 6 presents the distribution of the individuals tested according to the following ranges of VM: impaired  $\log(\text{VM}) < 0.4$ ,  $\text{VM} < 2.5$ , number of patients 351 (33%), acceptable  $0.4 \leq \log(\text{VM}) < 0.9$ ,  $2.5 \leq \text{VM} < 8$ , number of patients 343 (32%) and optimal  $\log(\text{VM}) \geq 0.9$ ,  $\text{VM} \geq 8$ , number of patients 369 (35%) with partition into control and CVD+DM2 groups.



**Figure 6.** Distribution of patients according to the selected VM parameter values.

## 5. Conclusions

Although flowmotion analysis has been successfully used to assess microcirculation dysfunction in numerous disease entities, it has not yet become common clinical practice [42], mainly due to difficult measurement methodology, requiring complicated analysis of results. Unlike most methods, the FMSF signal enables direct visualization of flowmotion oscillations under both normoxic and hyperemic/reperfusion conditions.

While many diseases are accompanied by a flowmotion disorder, or perhaps this disorder even precedes the main symptoms of the disease itself, there are numerous cases where the compensatory effect of myogenic microvasculatory adaptation to hypoxia can support the functioning of the body, as well as numerous examples of a complete lack of myogenic oscillations and their activation. Both conditions can be diagnosed either on the basis of a response to hypoxia, observed with the use of PORH provocation (log(HS) parameter) or on the basis of the predicted response from myogenic oscillations under normoxic conditions (log(VM) parameter). Both of these values remain strongly correlated with each other and similarly weaken with age. Optimal myogenic oscillations under normoxia conditions guarantee a good response to hypoxia under disease conditions. Their absence indicates a lack of support from microcirculatory flowmotion in combating hypoxic condition. In the large group of cardiovascular and type 2 diabetic patients studied here, a significant proportion of them (one third) were deprived of such support. Similarly, decreased VM has been observed for patients with androgen deficiency [43], depression, and cancer (preliminary results).

If we consider HS as a measure of the microcirculation response to hypoxia, then VM can be considered a measure of microcirculatory readiness to provide this response. Thus, a simple, quick measurement without occlusion might have significant diagnostic value for the health care workers. Such a less time-consuming measurement would be less harmful for the patient and more convenient for children and disabled people. It could be more easily introduced into the daily practice of athletes. Moreover, flowmotion assessment does not have to be limited to the upper limb, but can be performed on any part of the body using a movable measuring head.

**Author Contributions:** AM analysed the data and prepared the manuscript. JK contributed to data collection and to manuscript visualization. AS contributed to the design of the IHT study. JG performed the literature search and revised the manuscript.

**Funding:** This work was supported by the European Union from the resources of the European Regional Development Fund under the Smart Growth Operational Program, Grant No. POIR 01.01.01-00-0540/15-00.

**Institutional Review Board Statement:** This is an article presenting a new concept for analysing the results of clinical trials previously described in detail in the original articles. Relevant ethics committee approvals are detailed there.

**Conflicts of Interest:** JG and AM are inventors of the patents protecting the use of FMSF technology.

## References

1. Nilsson, H.; Aalkjaer, C. Vasomotion: Mechanisms and Physiological Importance. *Mol. Interv.* **2003**, *3*, 79–89. <https://doi.org/10.1124/mi.3.2.79>.
2. Aalkjær, C.; Boedtkjer, D.; Matchkov, V. Vasomotion – What Is Currently Thought? *Acta Physiol.* **2011**, *202*, 253–269. <https://doi.org/10.1111/j.1748-1716.2011.02320.x>.
3. Hong, K.-S.; Lee, M.-G. Rescue Effect of Exercise on Impaired Arteriolar Myogenic Response with Advancing Age. *Exerc. Sci.* **2017**, *26*, 8–16. <https://doi.org/10.15857/ksep.2017.26.1.8>.
4. Fredriksson, I.; Larsson, M.; Strömberg, T.; Iredahl, F. Vasomotion Analysis of Speed Resolved Perfusion, Oxygen Saturation, Red Blood Cell Tissue Fraction, and Vessel Diameter: Novel Microvascular Perspectives. *Ski. Res. Technol.* **2022**, *28*, 142–152. <https://doi.org/10.1111/srt.13106>.
5. Kim, D. H.; Choi, J. Y.; Kim, S. M.; Son, S.-M.; Choi, S.-Y.; Koo, B.; Rah, C.-S.; Nam, J. H.; Ju, M. J.; Lee, J. S.; You, R. Y.; Hong, S. H.; Lee, J.; Bae, J.-W.; Kim, C. H.; Choi, W.; Kim, H. S.; Xu, W.-X.; Lee, S. J.; Kim, Y. C.; Yun, H.-Y. Vasomotion in Human Arteries and Their Regulations Based on Ion Channel Regulations: 10 Years Study. *J. Cell. Physiol.* **2023**, *238*, 2076–2089. <https://doi.org/10.1002/jcp.31067>.
6. Rossi, M.; Carpi, A.; Galetta, F.; Franzoni, F.; Santoro, G. The Investigation of Skin Blood Flowmotion: A New Approach to Study the Microcirculatory Impairment in Vascular Diseases? *Biomed. Pharmacother.* **2006**, *60*, 437–442. <https://doi.org/10.1016/j.biopha.2006.07.012>.
7. Bruning, R. S.; Kenney, W. L.; Alexander, L. M. Altered Skin Flowmotion in Hypertensive Humans. *Microvasc. Res.* **2015**, *97*, 81–87. <https://doi.org/10.1016/j.mvr.2014.01.001>.
8. Tikhonova, I. V.; Kosyakova, N. I.; Tankanag, A. V.; Chemeris, N. K. Oscillations of Skin Microvascular Blood Flow in Patients with Asthma. *Microcirculation* **2016**, *23*, 33–43. <https://doi.org/10.1111/micc.12252>.
9. Mizeva, I.; Makovik, I.; Dunaev, A.; Krupatkin, A.; Meglinski, I. Analysis of Skin Blood Microflow Oscillations in Patients with Rheumatic Diseases. *J. Biomed. Opt.* **2017**, *22*, 070501. <https://doi.org/10.1117/1.JBO.22.7.070501>.
10. Gebicki, J.; Katarzynska, J.; Cholewinski, T.; Sieron, L.; Marcinek, A. Flowmotion Monitored by Flow Mediated Skin Fluorescence (FMSF): A Tool for Characterization of Microcirculatory Status. *Front. Physiol.* **2020**, *11*, 702. <https://doi.org/10.3389/FPHYS.2020.00702>.
11. Stefanovska, A.; Bracic, M.; Kvernmo, H. D. Wavelet Analysis of Oscillations in the Peripheral Blood Circulation Measured by Laser Doppler Technique. *IEEE Trans. Biomed. Eng.* **1999**, *46*, 1230–1239. <https://doi.org/10.1109/10.790500>.
12. Hellmann, M.; Roustit, M.; Cracowski, J. L. Skin Microvascular Endothelial Function as a Biomarker in Cardiovascular Diseases? *Pharmacol. Rep.* **2015**, *67*, 803–810. <https://doi.org/10.1016/j.pharep.2015.05.008>.
13. Cracowski, J.-L.; Roustit, M. Current Methods to Assess Human Cutaneous Blood Flow: An Updated Focus on Laser-Based-Techniques. *Microcirculation* **2016**, *23*, 337–344. <https://doi.org/10.1111/micc.12257>.
14. Cracowski, J.-L.; Roustit, M. Human Skin Microcirculation. In *Comprehensive Physiology*; Prakash, Y.S., Ed.; Wiley: New York, NY, USA, 2020; Chapter 3, Volume 10, 2020; pp 1105–1154. <https://doi.org/10.1002/cphy.c190008>.
15. Szczepanek, E.; Marczyk, B.; Chukwu, O.; Chlopicki, S.; Sacha, T. Endothelial Function in Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors Is Not Related to Cardiovascular Risk Assessed by the Systematic Coronary Risk Estimation 2 Algorithm. *Polish Arch. Intern. Med.* **2024**, *134*, 1–9. <https://doi.org/10.20452/pamw.16719>.
16. Kvernmo, H. D.; Stefanovska, A.; Kirkeboen, K. A.; Kvernebo, K. Oscillations in the Human Cutaneous Blood Perfusion Signal Modified by Endothelium-Dependent and Endothelium-Independent Vasodilators. *Microvasc. Res.* **1999**, *57*, 298–309. <https://doi.org/10.1006/mvre.1998.2139>.

17. Kvandal, P.; Landsverk, S. A.; Bernjak, A.; Stefanovska, A.; Kvernmo, H. D.; Kirkeboen, K. A. Low-Frequency Oscillations of the Laser Doppler Perfusion Signal in Human Skin. *Microvasc. Res.* **2006**, *72*, 120–127. <https://doi.org/10.1016/j.mvr.2006.05.006>.
18. Söderström, T.; Stefanovska, A.; Veber, M.; Svensson, H. Involvement of Sympathetic Nerve Activity in Skin Blood Flow Oscillations in Humans. *Am. J. Physiol. Circ. Physiol.* **2003**, *284*, H1638–H1646. <https://doi.org/10.1152/ajpheart.00826.2000>.
19. Aalkjaer, C.; Nilsson, H. Vasomotion: Cellular Background for the Oscillator and for the Synchronization of Smooth Muscle Cells. *Br. J. Pharmacol.* **2005**, *144*, 605–616. <https://doi.org/10.1038/sj.bjp.0706084>.
20. Cracowski, J.-L.; Minson, C. T.; Salvat-Melis, M.; Halliwill, J. R. Methodological Issues in the Assessment of Skin Microvascular Endothelial Function in Humans. *Trends Pharmacol. Sci.* **2006**, *27*, 503–508. <https://doi.org/10.1016/j.tips.2006.07.008>.
21. Stewart, J. M.; Indu, T.; Michael S, G.; and Medow, M. S. Noninvasive Measure of Microvascular Nitric Oxide Function in Humans Using Very Low-Frequency Cutaneous Laser Doppler Flow Spectra. *Microcirculation* **2007**, *14*, 169–180. <https://doi.org/10.1080/10739680601139179>.
22. Hodges, G. J.; Mallette, M. M.; Martin, Z. T.; Del Pozzi, A. T. Effect of Sympathetic Nerve Blockade on Low-Frequency Oscillations of Forearm and Leg Skin Blood Flow in Healthy Humans. *Microcirculation* **2017**, *24*, e12388. <https://doi.org/10.1111/micc.12388>.
23. Zhao, X.; Schalkwijk, C.; Kroon, A.; Schram, M. T.; Stehouwer, C.; Houben, A. Different Measures of Hyperglycemia Are Negatively Associated With Skin Microvascular Flowmotion: The Maastricht Study. *Microcirculation* **2024**, *31*, e12882. <https://doi.org/https://doi.org/10.1111/micc.12882>.
24. Katarzynska, J.; Lipinski, Z.; Cholewinski, T.; Piotrowski, L.; Dworzynski, W.; Urbaniak, M.; Borkowska, A.; Cypriak, K.; Purgal, R.; Marcinek, A.; Gebicki, J. Non-Invasive Evaluation of Microcirculation and Metabolic Regulation Using Flow Mediated Skin Fluorescence (FMSF): Technical Aspects and Methodology. *Rev. Sci. Instrum.* **2019**, *90*, 104104. <https://doi.org/10.1063/1.5092218>.
25. Hellmann, M.; Tarnawska, M.; Dudziak, M.; Dorniak, K.; Roustit, M.; Cracowski, J. L. Reproducibility of Flow Mediated Skin Fluorescence to Assess Microvascular Function. *Microvasc. Res.* **2017**, *113*, 60–64. <https://doi.org/10.1016/j.mvr.2017.05.004>.
26. Tarnawska, M.; Dorniak, K.; Kaszubowski, M.; Dudziak, M.; Hellmann, M. A Pilot Study with Flow Mediated Skin Fluorescence: A Novel Device to Assess Microvascular Endothelial Function in Coronary Artery Disease. *Cardiol. J.* **2018**, *25*, 120–127. <https://doi.org/10.5603/CJ.a2017.0096>.
27. Marcinek, A.; Katarzynska, J.; Sieron, L.; Skokowski, R.; Zielinski, J.; Gebicki, J. Non-Invasive Assessment of Vascular Circulation Based on Flow Mediated Skin Fluorescence (FMSF). *Biology.* **2023**, *12*, 385. <https://doi.org/10.3390/biology12030385>.
28. Marcinek, A.; Katarzynska, J.; Gebicki, J. A New Approach to Vascular Screening: Identification of Impaired Vascular Function Using the FMSF Technique. *Sensors.* **2024**, *24*, 1721. <https://doi.org/10.3390/s24061721>.
29. Marcinek, A.; Katarzynska, J.; Gebicki, J. Simultaneous Assessment of Mitochondrial and Vascular Function Using the Flow Mediated Skin Fluorescence Technique. *Front. Physiol.* **2025**, *16*, 1509159. <https://doi.org/10.3389/fphys.2025.1509159>.
30. Cole, W. C.; Gordon, G. R.; Braun, A. P. Cellular and Ionic Mechanisms of Arterial Vasomotion. In *Smooth Muscle Spontaneous Activity: Physiological and Pathological Modulation*; Hashitani, H., Lang, R. J., Eds.; Springer: Singapore, Singapore, 2019, Volume 1124, pp 297–312. [https://doi.org/10.1007/978-981-13-5895-1\\_12](https://doi.org/10.1007/978-981-13-5895-1_12).
31. Liu, P.; Bi, T.; Du, G.; Yan, L.; Hou, H. Dynamic Non-Invasive Detection of NADH Based on Blood Flow-Mediated Skin Fluorescence (FMSF) Method. *Open J. Appl. Sci.* **2024**, *14*, 1437–1453. <https://doi.org/10.4236/ojapps.2024.146095>.
32. Li, J.; Zhang, Y.; Zhang, D.; Wang, W.; Xie, H.; Ruan, J.; Jin, Y.; Li, T.; Li, X.; Zhao, B.; Zhang, X.; Lin, J.; Shi, H.; Jia, J.-M. Ca<sup>2+</sup> Oscillation in Vascular Smooth Muscle Cells Control Myogenic Spontaneous Vasomotion and Counteract Post-Ischemic No-Reflow. *Commun. Biol.* **2024**, *7*, 332. <https://doi.org/10.1038/s42003-024-06010-1>.

33. Thorn, C. E.; Shore, A. C. The Role of Perfusion in the Oxygen Extraction Capability of Skin and Skeletal Muscle. *Am. J. Physiol. Circ. Physiol.* **2016**, *310*, H1277–H1284. <https://doi.org/10.1152/ajpheart.00047.2016>.
34. Davies, T.; Gilbert-Kawai, E.; Wythe, S.; Meale, P.; Mythen, M.; Levett, D.; Mitchell, K.; Grocott, M.; Clough, G.; Martin, D.; Group, for the X. E. 2 R. Sustained Vasomotor Control of Skin Microcirculation in Sherpas versus Altitude-Naive Lowlanders: Experimental Evidence from Xtreme Everest 2. *Exp. Physiol.* **2018**, *103*, 1494–1504. <https://doi.org/10.1113/EP087236>.
35. Carey, D.; Thanaj, M.; Davies, T.; Gilbert-Kawai, E.; Mitchell, K.; Levett, D. Z. H.; Mythen, M. G.; Martin, D. S.; Grocott, M. P.; Chipperfield, A. J.; Clough, G. F. Enhanced Flow-Motion Complexity of Skin Microvascular Perfusion in Sherpas and Lowlanders during Ascent to High Altitude. *Sci. Rep.* **2019**, *9*, 14391. <https://doi.org/10.1038/s41598-019-50774-0>.
36. Salvi, P.; Faini, A.; Castiglioni, P.; Brunacci, F.; Montaguti, L.; Severi, F.; Gautier, S.; Pretolani, E.; Benetos, A.; Parati, G. Increase in Slow-Wave Vasomotion by Hypoxia and Ischemia in Lowlanders and Highlanders. *J. Appl. Physiol.* **2018**, *125*, 780–789. <https://doi.org/10.1152/jappphysiol.00977.2017>.
37. Mikosiński, J.; Mikosiński, P.; Kwapisz, A.; Katarzynska, J.; Gebicki, J. Conclusions from an Observational Study of Patients with Vascular Diseases Using the FMSF Technique. *Vasc. Health Risk Manag.* **2023**, *19*, 755–764. <https://doi.org/10.2147/VHRM.S442344>.
38. Katarzynska, J.; Borkowska, A.; Czajkowski, P.; Los, A.; Szczerbinski, L.; Milewska-Kranc, A.; Marcinek, A.; Kretowski, A.; Cypryk, K.; Gebicki, J. Flow Mediated Skin Fluorescence Technique Reveals Remarkable Effect of Age on Microcirculation and Metabolic Regulation in Type 1 Diabetes. *Microvasc. Res.* **2019**, *124*, 19–24. <https://doi.org/10.1016/j.mvr.2019.02.005>.
39. Katarzynska, J.; Borkowska, A.; Los, A.; Marcinek, A.; Cypryk, K.; Gebicki, J. Flow-Mediated Skin Fluorescence (FMSF) Technique for Studying Vascular Complications in Type 2 Diabetes. *J. Diabetes Sci. Technol.* **2020**, *14*, 693–694. <https://doi.org/10.1177/1932296819895544>.
40. Bugaj, O.; Zieliński, J.; Kusy, K.; Kantanista, A.; Wieliński, D.; Guzik, P. The Effect of Exercise on the Skin Content of the Reduced Form of NAD and Its Response to Transient Ischemia and Reperfusion in Highly Trained Athletes. *Front. Physiol.* **2019**, *10*, 600. <https://doi.org/10.3389/fphys.2019.00600>.
41. Bugaj, O.; Kusy, K.; Kantanista, A.; Korman, P.; Wieliński, D.; Zieliński, J. The Effect of a 7-Week Training Period on Changes in Skin NADH Fluorescence in Highly Trained Athletes. *Appl. Sci.* **2020**, *10*, 5133. <https://doi.org/10.3390/app10155133>.
42. Chudzik, M.; Cender, A.; Mordaka, R.; Zieliński, J.; Katarzyńska, J.; Marcinek, A.; Gebicki, J. Chronic Fatigue Associated with Post-COVID Syndrome versus Transient Fatigue Caused by High-Intensity Exercise: Are They Comparable in Terms of Vascular Effects? *Vasc. Health Risk Manag.* **2022**, *18*, 711–719. <https://doi.org/10.2147/VHRM.S371468>.
43. Slowikowska-Hilczer, J.; Walczak-Jedrzejowska, R.; Adamczewska, D.; Byczkiewicz, P.; Marchlewska, K.; Katarzynska, J.; Gebicki, J. A New Approach to the Assessment of Erectile Dysfunction Based on Vasomotion Monitored by the Flow-Mediated Skin Fluorescence (FMSF) Technique—A Preliminary Study. *J. Clin. Med.* **2024**, *13*, 3210. <https://doi.org/10.3390/jcm13113210>.
44. Jewell, U. R.; Kvietikova, I.; Scheid, A.; Bauer, C.; Wenger, R. H.; Gassmann, M. Induction of HIF-1 $\alpha$  in Response to Hypoxia Is Instantaneous. *FASEB J.* **2001**, *15*, 1312–1314. <https://doi.org/10.1096/fj.00-0732fje>.
45. Marcinek, A.; Katarzynska, J.; Cypryk, K.; Los-Stegienta, A.; Slowikowska-Hilczer, J.; Walczak-Jedrzejowska, R.; Zieliński, J.; Gebicki, J. Assessment of Microvascular Function Based on Flowmotion Monitored by the Flow-Mediated Skin Fluorescence Technique. *Biosensors.* **2024**, *14*, 459. <https://doi.org/10.3390/bios14100459>.
46. Rossi, M.; Carpi, A.; Di Maria, C.; Galetta, F.; Santoro, G. Spectral Analysis of Laser Doppler Skin Blood Flow Oscillations in Human Essential Arterial Hypertension. *Microvasc. Res.* **2006**, *72*, 34–41. <https://doi.org/10.1016/j.mvr.2006.04.001>.

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s)

disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.f